DISEASE INDICATIONS:
Alagille syndrome

MANUFACTURER:
Mirum Pharmaceuticals

USAGE:
Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Livmarli (maralixibat) is a medication used to treat pruritus (itching) associated with Alagille syndrome in patients aged 1 month and above.